Contemporary Oncology®: Biomarkers, Pathways, and Targeted Therapies® - May 2022
Emerging Targeted Therapies Continue to Shift Paradigm in EGFR Exon 20–Mutated NSCLC
May 12th 2022Edward Kim, MD, MBA, discussed the facets of each presentation from the meeting, featuring other emerging targeted therapies in NSCLC, biomarker testing in the space, frontline immunotherapy in NSCLC, and the current management of small cell lung cancer.
HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity
May 8th 2022HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.
Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer
May 1st 2022Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.
